Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948)
about
Optimal combination of antiangiogenic therapy for hepatocellular carcinomaAntiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.DDMC-p53 gene therapy with or without cisplatin and microwave ablation.A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies.Interstitial Fluid Pressure Correlates Clinicopathological Factors of Lung Cancer.Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer.Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.Therapeutic targeting of platelet-derived growth factor receptors in solid tumors.Current and future intratumoral targeted treatment for pancreatic cancer.Intratumoral gene therapy versus intravenous gene therapy for distant metastasis control with 2-diethylaminoethyl-dextran methyl methacrylate copolymer non-viral vector-p53.Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical modeling?Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.Interstitial fluid pressure of thymic epithelial tumours.Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
P2860
Q26799458-EF85E485-7F03-4028-B698-A92F6688453BQ30399006-E5CFF0AF-B990-426A-B47A-9383DF7844AFQ30542073-AB0B6D94-41F3-4B9B-9539-87A735DFBE8CQ33276211-556D6E07-0165-4102-A3AE-0CACA4C08088Q35062862-C90DF142-0A46-4298-B63A-9BEF71DE7B85Q35654976-5CFB9103-2293-4FE2-A115-102AAAE7C2CBQ36082501-57B37F7F-D703-407E-AB84-886086192549Q36306066-7EC11106-279C-4B14-BA4F-9AE63E86B80AQ37033793-E556F564-2635-4BC6-AFF2-8601143EDA5BQ37186812-2A24072F-6DF2-4CB9-84E0-B4809E56FC8CQ37340643-2994FB6B-6B08-4140-B797-7913606DF0A1Q37377316-B12DC1D1-41C2-4BD2-BDC1-D3D59FA2D56CQ38103397-1FC9BAF5-75EC-4E64-8112-530D13915347Q38160946-291E0296-DFDE-4D90-80E4-AF9C5E1E18FFQ38261961-7E9291AE-53B3-4FC4-8690-F53EA5E10E4FQ38451785-3E1E8287-DC94-470F-B108-F5352CF15C0BQ43141618-159AEEAB-903A-4BFF-A628-9307A57E54F2Q46138405-0D0B2BA0-3FCB-40F1-9281-A4381F96727BQ47758918-97EF6BCD-A4EC-4A90-8E25-DC525D56B0F7Q52676764-88C75035-E7AA-4811-ADFD-57CC204F7DAE
P2860
Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948)
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Effects of sorafenib on intra- ...... y sarcomas (NCI protocol 6948)
@ast
Effects of sorafenib on intra- ...... y sarcomas (NCI protocol 6948)
@en
Effects of sorafenib on intra- ...... y sarcomas (NCI protocol 6948)
@nl
type
label
Effects of sorafenib on intra- ...... y sarcomas (NCI protocol 6948)
@ast
Effects of sorafenib on intra- ...... y sarcomas (NCI protocol 6948)
@en
Effects of sorafenib on intra- ...... y sarcomas (NCI protocol 6948)
@nl
prefLabel
Effects of sorafenib on intra- ...... y sarcomas (NCI protocol 6948)
@ast
Effects of sorafenib on intra- ...... y sarcomas (NCI protocol 6948)
@en
Effects of sorafenib on intra- ...... y sarcomas (NCI protocol 6948)
@nl
P2093
P2860
P1433
P1476
Effects of sorafenib on intra- ...... y sarcomas (NCI protocol 6948)
@en
P2093
Chandrajit P Raut
Dan G Duda
George D Demetri
J Paul Eder
Jeffrey A Morgan
Johanna Lahdenranta
Marek Ancukiewicz
Rakesh K Jain
Richard Quek
Yves Boucher
P2860
P304
P356
10.1371/JOURNAL.PONE.0026331
P407
P577
2012-01-01T00:00:00Z